Osteomyelofibrose

Baxter EJ et al. () Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Kralovics R et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Méndez-Ferrer S et al. (2008) Haematopoietic stem cell release is regulated by circadian oscillations.

Méndez-Ferrer S et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche.

Arranz L et al. (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.

Delhommeau F et al. (2009) Mutation in TET2 in myeloid cancers.

Sieff CA et al. (1980) Familial myelofibrosis.

Bonduel M et al. (1998) Familial idiopathic myelofibrosis and multiple hemangiomas.

Pikman Y et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pardanani AD et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Kaufmann KB et al. (2012) A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.

Jutzi JS et al. (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.

Cazzola M et al. (2014) JAK inhibitor in CALR-mutant myelofibrosis.

Passamonti F et al. (2014) JAK inhibitor in CALR-mutant myelofibrosis.

Cassinat B et al. (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia.

Orphanet article

OMIM.ORG article

Wikipedia Artikel